Patents by Inventor David J. Rawson

David J. Rawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirocyclic derivatives
    Patent number: 7507742
    Abstract: The invention provides compounds of formula (I): wherein: m is 0, 1 or 2; X is O, S or N—CN; R is F, Cl or CN; A is a C3-6 cycloalkylene group optionally substituted with a C1-4 alkyl group; and B is a single bond or a C1-2 alkylene group; or a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. The compounds are PDE7 inhibitors and have a number of therapeutic applications, particularly in the treatment of pain, especially neuropathic pain.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: March 24, 2009
    Assignee: Pfizer Inc.
    Inventors: David J. Rawson, Nigel A. Swain
  • Substituted glycine derivatives for use as medicaments
    Publication number: 20040092498
    Abstract: The compounds of formula (I) are substituted glycine derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.
    Type: Application
    Filed: August 13, 2003
    Publication date: May 13, 2004
    Inventors: David Blakemore, Justin S. Bryans, Wai-Lam Alex Chu, Graham N. Maw, David J. Rawson, Lisa R. Thompson
  • Cyclic sulfone derivatives
    Patent number: 5883131
    Abstract: A compound of the formula ##STR1## wherein n, p, q, X, Y, Z and Ar are as defined herein, useful in the treatment of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis or other diseases characterized by matrix metalloprotenase activity, as well as AIDS, sepsis, septic shock or other diseases involving the production of TNF.
    Type: Grant
    Filed: July 9, 1997
    Date of Patent: March 16, 1999
    Assignee: Pfizer Inc.
    Inventors: Laurence E. Burgess, James P. Rizzi, David J. Rawson